Understanding Treatment-Resistant Depression

Treatment-resistant depression (TRD) is generally defined as major depressive disorder (MDD) that has not responded adequately to at least two different antidepressant medications given at therapeutic doses for sufficient duration (typically 6-8 weeks each). Approximately 30% of individuals with MDD meet criteria for treatment resistance (Rush et al., STAR*D trial, 2006).

TRD represents a significant clinical challenge. The STAR*D trial demonstrated that remission rates dropped from ~37% with the first antidepressant to approximately 13% by the fourth treatment attempt.

Why Ketamine Is Different

Traditional antidepressants (SSRIs, SNRIs, tricyclics, MAOIs) primarily modulate monoamine neurotransmitters and typically require 4-8 weeks before clinical effects emerge. Ketamine operates through a fundamentally different mechanism — glutamatergic modulation via NMDA receptor antagonism.

Key differentiators include:

  • Rapid onset: Antidepressant effects can emerge within hours of a single infusion
  • Novel mechanism: By targeting the glutamate system rather than monoamines, ketamine addresses depression through pathways that previous treatments did not engage
  • Neuroplasticity promotion: Ketamine rapidly increases synaptic connectivity in brain regions affected by chronic depression, particularly the prefrontal cortex

What the Evidence Shows

  • Response rates: Meta-analyses indicate approximately 50-70% of TRD patients respond to an initial series of IV ketamine infusions (Caddy et al., 2015; Kishimoto et al., 2016)
  • Remission rates: Approximately 30-40% achieve full remission following an induction series
  • Speed of response: Zarate et al. (2006) demonstrated significant improvement within 2 hours of a single IV infusion
  • Durability: Individual infusion effects typically last 1-3 weeks. Maintenance protocols with periodic booster infusions can extend benefits

Clinical Protocol for TRD

  • Induction phase: Six IV infusions over 2-3 weeks (typically 0.5 mg/kg over 40 minutes)
  • Assessment: Depression severity measured using validated scales (PHQ-9, MADRS, or HAM-D)
  • Maintenance phase: Booster infusions at individually tailored intervals, commonly every 2-6 weeks
  • Adjunctive therapy: Most effective as part of a comprehensive plan including ongoing psychotherapy and medication optimization

Spravato (Esketamine) for TRD

The FDA approved Spravato (esketamine nasal spray) in 2019 specifically for TRD in conjunction with an oral antidepressant. It must be administered under direct supervision in a certified REMS healthcare setting with at least 2 hours of post-dose monitoring.

Important Considerations

Patients should have a confirmed TRD diagnosis with documented treatment failures, be screened for contraindications, maintain ongoing psychiatric care, and understand ketamine is most effective as part of a multimodal approach.

This article is for informational purposes only. Consult a qualified healthcare provider to determine if ketamine therapy is appropriate for your situation.